| 0.1681 -0.011 (-6.09%) | 06-18 10:08 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.31 | 1-year : | 0.41 |
| Resists | First : | 0.27 | Second : | 0.35 |
| Pivot price | 0.17  |
|||
| Supports | First : | 0.14 | Second : | 0.11 |
| MAs | MA(5) : | 0.17 |
MA(20) : | 0.18 |
| MA(100) : | 0.7 |
MA(250) : | 1.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.7 |
D(3) : | 33.4 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 3.86 | Low : | 0.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GOSS ] has closed below upper band by 33.4%. Bollinger Bands are 87.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 67 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.19 - 0.19 | 0.19 - 0.19 |
| Low: | 0.15 - 0.15 | 0.15 - 0.15 |
| Close: | 0.18 - 0.18 | 0.18 - 0.18 |
Gossamer Bio, Inc. operates as a U.S.-based, clinical-stage biopharmaceutical company. Its primary objective is to discover, acquire, advance, and market novel therapeutic solutions, specifically addressing conditions within immunology, inflammatory diseases, and oncology. The company's pipeline highlights several key drug candidates: GB002: An inhaled small molecule designed to inhibit platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT, currently being developed for pulmonary arterial hypertension. GB004: An oral, gut-targeted small molecule in development for treating inflammatory bowel disease. GB5121: An oral, irreversible covalent small molecule that targets Bruton's Tyrosine Kinase (BTK), intended for primary central nervous system lymphoma. GB7208: Another oral small molecule BTK inhibitor, under investigation for multiple sclerosis. To support its drug development initiatives, Gossamer Bio has forged strategic licensing partnerships. It holds agreements with Pulmokine, Inc. for the advancement and commercialization of GB002 and its associated backup compounds. Additionally, the company collaborates with Aerpio Pharmaceuticals, Inc. regarding GB004 and related chemical entities. Founded in 2015, the enterprise was initially known as FSG, Bio, Inc. before rebranding as Gossamer Bio, Inc. in 2017. Its corporate headquarters are situated in San Diego, California.
Thu, 18 Jun 2026
Gossamer Bio Insiders Are Down US$45k But Regain Some Losses - simplywall.st
Thu, 18 Jun 2026
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Wed, 17 Jun 2026
Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ... By GuruFocus - Investing.com Canada
Wed, 17 Jun 2026
683 Capital Management, LLC Acquires Significant Stake in Gossamer Bio Inc - GuruFocus
Wed, 17 Jun 2026
Gossamer Bio final tender results: $72M new notes, 317.6M shares available; $18.95M old notes remain - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 489 (M) |
| Shares Float | 178 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 75.1 (%) |
| Shares Short | 62,820 (K) |
| Shares Short P.Month | 40,020 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.69 |
| Profit Margin | 0 % |
| Operating Margin | -264.7 % |
| Return on Assets (ttm) | -52.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 71.5 % |
| Gross Profit (p.s.) | 0.11 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -170 (M) |
| Levered Free Cash Flow | -97 (M) |
| PE Ratio | -0.25 |
| PEG Ratio | 0 |
| Price to Book value | -0.28 |
| Price to Sales | 1.69 |
| Price to Cash Flow | -0.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|